External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

<ul><li>Gossamer Bio is developing seralutinib for PAH in Phase 3 clinical trials</li><li>Recent changes in C-suite, insider stock purchases, and partnerships with pharmaceutical companies</li><li>Company has ample cash and near-term catalysts for high upside potential in treating PAH, a serious hemodynamic disorder.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Gossamer Bio is developing seralutinib for PAH in Phase 3 clinical trialsRecent changes in C-suite, insider stock purchases, and partnerships with pharmaceutical companiesCompany has ample cash and near-term catalysts for high upside potential in treating PAH, a serious hemodynamic disorder.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Gossamer Bio Inc (GOSS) - Monday, Aug 26, 2024

United States

Gossamer Bio, Inc. operates as a biopharmaceutical company. The Company focuses on discovering, acquiring, and developing therapeutics in the disease areas of immunology, inflammation, and oncology. Gossamer Bio serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Gossamer Bio Inc (GOSS US)

Gossamer Bio Inc (GOSS) - Monday, Aug 26, 2024

Gossamer Bio is developing seralutinib for PAH in Phase 3 clinical trials. Recent changes in C-suite, insider stock purchases, and partnerships...

Value Investors Club (VIC)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)